We are live on ! Find out more
UBX

Unity Biotechnology
UBX

Delisted

UBX was delisted on the 8th of July, 2025.

Back to rankings

6 hedge funds and large institutions have $1.68K invested in Unity Biotechnology in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

14.83% less ownership

Funds ownership: 15% → 0.17% (-15%)

83% less funds holding

Funds holding: 35 → 6 (-29)

97% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 30

100% less capital invested

Capital invested by funds: $987K → $1.68K (-$986K)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
6
Holders Change
-29
Holders Change %
-82.86%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$4.01K

Top Sellers

Rank Fund Capital Flow
1
AVM
Arch Venture Management
Illinois
-$386K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$256K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$64.2K
4
UBS Group
UBS Group
Switzerland
-$58.5K
5
Renaissance Technologies
Renaissance Technologies
New York
-$37.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
1
Osaic Holdings
Arizona
$831 -$29 -100 -0.8%
XT
2
XTX Topco
Cayman Islands
$782 +$4.01K +13,985 New
SPIA
3
Steward Partners Investment Advisory
New York
$56 – -1 -0.1%
AIP
4
Ameritas Investment Partners
Nebraska
$6 – – –
AWM
5
AllSquare Wealth Management
New York
$3 – – –
AVM
6
Arch Venture Management
Illinois
– -$386K -1,004,817 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$256K -673,090 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– -$64.2K -169,025 Closed
UBS Group
9
UBS Group
Switzerland
– -$58.5K -152,327 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$37.8K -98,311 Closed
BlackRock
11
BlackRock
New York
– -$31.3K -81,402 Closed
Morgan Stanley
12
Morgan Stanley
New York
– -$23.3K -60,556 Closed
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$21.6K -56,720 Closed
FFVM
14
Founders Fund V Management
California
– -$18.7K -49,172 Closed
State Street
15
State Street
Massachusetts
– -$14.4K -37,824 Closed
Northern Trust
16
Northern Trust
Illinois
– -$13.6K -35,452 Closed
HF
17
HRT Financial
New York
– -$13K -34,641 Closed
SWM
18
SeaCrest Wealth Management
New York
– -$10.7K -27,800 Closed
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
– -$10K -26,142 Closed
BCM
20
Bridgeway Capital Management
Texas
– -$9.5K -25,000 Closed
EWM
21
Endowment Wealth Management
Wisconsin
– -$4.79K -12,475 Closed
Group One Trading
22
Group One Trading
Illinois
– -$3.98K -10,484 Closed
SS
23
SBI Securities
Japan
– -$1.86K -4,834 Closed
TRCT
24
Tower Research Capital (TRC)
New York
– -$920 -2,395 Closed
GEA
25
Glen Eagle Advisors
New Jersey
– -$746 -1,942 Closed
1
2

UBX Hedge Fund Activity: Q3 2025 in Review

6 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2025, worth a combined $1.68K — down 100% from $987K a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of UBX and 1 opened new positions — a net loss of 29 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $4.01K. The largest seller was Arch Venture Management, exiting entirely with an estimated $386K sold.

  • 6 institutional investors held Unity Biotechnology (UBX) as of Q3 2025, down from 35 in Q2 2025.
  • Funds reported $1.68K of Unity Biotechnology stock for Q3 2025, down 100% quarter-over-quarter.
  • 1 fund opened new Unity Biotechnology positions in Q3 2025 and 30 closed out, a net change of -29 holders.
  • The largest Unity Biotechnology buyer in Q3 2025 was XTX Topco, an estimated $4.01K added.
  • The largest Unity Biotechnology seller in Q3 2025 was Arch Venture Management, an estimated $386K sold.

Based on aggregated 13F filings for Q3 2025.